Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial
about
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesOne-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialGlucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseInsulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesUpdate on the treatment of type 2 diabetes mellitusEfficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitusCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesBrown spider (Loxosceles genus) venom toxins: tools for biological purposesTargets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes.Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.Anti-diabetic Agents in Type 2 Diabetes: A Review of New Data Presented and Discussed on the EASD meeting in Rome, 2008.Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analysesExenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.Obesity treatment: novel peripheral targets.Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.Role and development of GLP-1 receptor agonists in the management of diabetes.Exenatide Use in the Management of Type 2 Diabetes Mellitus.Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes.Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysisThe incretin system and cardiometabolic diseaseAn overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous systemThe evolving place of incretin-based therapies in type 2 diabetesRelationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
P2860
Q24235718-32071E3B-4E5C-43CA-B8D5-A6153902B281Q24240522-E8A6A414-5D1B-49B8-91A7-92BE7C503BD4Q24244739-9CB81B5A-A3A2-4B23-8DBE-99FC46560BACQ24642503-A5DDA0AB-45B4-4FEE-98A2-9B6BF509A7B7Q24656644-BE6984CA-7B6D-4A8A-A010-B29449598E85Q26752699-D2CFB905-4EF6-4298-B4B7-D7CA89CFEE9CQ26827183-C15BDC7B-6049-4281-AFBF-2579FB86D376Q26861313-C1E3085C-3784-47AA-A0A0-F4952AFC0B19Q28073342-40237976-FC9B-45B6-9923-F8217EC91A64Q28088578-F855B8DD-5DCC-424E-84D7-C34B3F4DB502Q28741419-F38C693E-DD19-4254-9FF6-109126C20CADQ28743436-3506B423-B6AE-4F71-879F-7DA8C218B489Q30374513-74C9A690-EB59-41F8-B065-A9FAA8C4D397Q30426407-8170D914-DAB0-4E72-868C-4A7C5AEF890EQ30438126-F4BED72F-D71B-408E-B46A-D701AB62B7B2Q30558739-342F4B54-A9AB-4F00-ABA9-EC22B4E50731Q31001326-3A9E2E16-5B56-4D13-89C4-3B264AA3F268Q31066859-E9175ACC-7927-4CAB-BBAF-7AD17DED1295Q33263806-FEEEAB5B-BFE4-4D37-B9C0-2FACD345B795Q33394779-B83C3DD4-8749-487A-93F8-5D13C2DBFA94Q33585766-7917DF04-4587-4055-95A5-F2F33C391A1AQ33606579-3ECB1A57-75BE-4555-B921-3B2070CECC17Q33607749-043054A3-3B97-4223-AF2A-11DD8391DAE0Q33607971-3BDFEAD2-5872-44CD-9408-9681755EF75CQ33633710-5AF79D80-0284-4645-B1E0-A24E856BA228Q33635830-338E5186-B976-4A95-B8DA-4C04AD3188E3Q33664114-E065F830-7CC4-45BC-B65F-86974F9A307EQ33664745-A034AB55-59AE-444F-B438-9975F5A37124Q33739048-80526B26-C217-4818-88A4-212AD864B118Q33751401-8C729C37-B42A-4CF5-BA73-517598874813Q33755744-595156BE-99BF-44A9-8CE2-AFFD58DA877DQ33767049-37EC9224-3ACF-4190-9EB5-DE5A25C45F7AQ33776092-4AAC3142-EDDF-4261-8CB6-CD2C44CE912FQ33786150-2D0D219F-4EBD-442E-8CFB-309B271E0F09Q33840311-24EDEBF4-B4CE-4A0A-807D-6308794D1399Q33866808-E26DE43C-31E8-437A-A19D-23A746E1684EQ33871459-608C914C-0D8D-4AE1-B229-7504F1796B5EQ33884913-218E7520-D500-4FE7-844A-B873E73E7A24Q33888236-9EAAD1DF-3229-430A-B94A-3908D3525991Q33932718-ECB32116-3784-4CAA-B8E9-5156D1D82305
P2860
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@ast
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@en
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@nl
type
label
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@ast
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@en
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@nl
prefLabel
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@ast
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@en
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@nl
P2093
P921
P3181
P1476
Exenatide versus insulin glarg ...... 2 diabetes: a randomized trial
@en
P2093
Luc F Van Gaal
Mario H Widel
Michael J Mihm
Robert G Brodows
Robert J Heine
P304
P3181
P356
10.7326/0003-4819-143-8-200510180-00006
P407
P577
2005-10-18T00:00:00Z